Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
MET fusion
i
Other names:
DFNB97, AUTS9, RCCP2, C-Met, HGFR, HGF Receptor, Met Proto-Oncogene, HGF/SF Receptor, Proto-Oncogene C-Met, Scatter Factor Receptor, Tyrosine-Protein Kinase Met, Hepatocyte Growth Factor Receptor, MET, MET Proto-Oncogene, Receptor Tyrosine Kinase
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
4233
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
MET amplification (66)
MET exon 14 deletion (3)
HER-2 amplification + MET amplification (1)
MET amplification + AXL amplification (1)
MET amplification (66)
MET exon 14 deletion (3)
HER-2 amplification + MET amplification (1)
MET amplification + AXL amplification (1)
›
Related tests:
Oncomine™ Dx Target Test (10)
Oncomine™ Dx Target Test (10)
Associations
(2)
News
Trials
Search handles
@AndresFCardonaZ
@StephenVLiu
@VivekSubbiah
@chulkimMD
Search handles
@AndresFCardonaZ
@StephenVLiu
@VivekSubbiah
@chulkimMD
Filter by
Latest
10ms
A report on MET fusions in NSCLC published @JTOonline by Dr. Jurgen Wolf & colleagues Prevalence approximately 0.29% Five different fusion partners identified and responses seen with MET TKI Tx Emerging biomarker in NSCLC and beyond! https://t.co/TB4rGReynn (@chulkimMD)
10 months ago
MET fusion
over1year
Case report @ClinicalLung showing a novel PRKAR1A:MET fusion in NSCLC with a dramatic response to crizotinib. #MET fusions are rare with multiple different fusion partners described and they may not all be equally actionable. More work needed here. https://t.co/WpZM1Cp17h (@StephenVLiu)
over 1 year ago
Clinical
|
PRKAR1A (Protein Kinase CAMP-Dependent Type I Regulatory Subunit Alpha)
|
MET fusion
|
Xalkori (crizotinib)
almost3years
Acquired Tertiary MET Resistance (MET D1228N and a Novel LSM8-MET Fusion) to Selpercatinib and Capmatinib in a Patient With KIF5B-RET–positive NSCLC With Secondary MET Amplification as Initial Resistance to Selpercatinib @JTOonline https://t.co/ZCmqRnarbu (@VivekSubbiah)
almost 3 years ago
Clinical
|
MET (MET proto-oncogene, receptor tyrosine kinase) • KIF5B (Kinesin Family Member 5B)
|
MET amplification • MET D1228N • MET fusion
|
Retevmo (selpercatinib) • Tabrecta (capmatinib)
almost3years
⭐️Acquired Tertiary MET Resistance (MET D1228N and a Novel LSM8-MET Fusion) to Selpercatinib and Capmatinib in a Patient With KIF5B-RET–positive NSCLC With Secondary MET Amplification as Initial Resistance to Selpercatinib @JTOonline @oncoOuLungCA https://t.co/PoShj6K8vu (@VivekSubbiah)
almost 3 years ago
Clinical
|
MET (MET proto-oncogene, receptor tyrosine kinase) • KIF5B (Kinesin Family Member 5B)
|
MET amplification • MET D1228N • MET fusion
|
Retevmo (selpercatinib) • Tabrecta (capmatinib)
3years
Tepotinib Efficacy in a Patient with Non‐Small Cell Lung Cancer with Brain Metastasis Harboring an HLA‐DRB1‐MET Gene Fusion https://t.co/YF1ezdaCDP (@AndresFCardonaZ)
3 years ago
Clinical
|
MET (MET proto-oncogene, receptor tyrosine kinase) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
|
MET fusion
|
Tepmetko (tepotinib)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login